Immune Disorder Treatments, Monoclonal Antibody

KiRA Biotech is focused on advancing immunology drug development, particularly targeting immune system disorders through the creation of novel immunomodulatory drugs. The company is led by a team of experienced professionals, including CEO Dan Baker, who has a strong background in clinical development and research in immunology. Under his leadership, KiRA Biotech aims to develop therapies that can effectively modulate the immune response, potentially offering new treatment options for conditions such as rheumatoid arthritis and other immune-related diseases. The company is also involved in collaborations aimed at exploring tolerogenic therapies, which could provide innovative approaches to managing autoimmune disorders.

The expertise within KiRA Biotech is further enhanced by its board and management team, which includes individuals with extensive experience in pharmaceutical development, business strategy, and scientific research. For instance, Associate Professor Georgina Clark leads research efforts focused on developing therapeutic antibodies for treating hematological malignancies and other cancers. The company is actively expanding its immunology-focused portfolio and capabilities, particularly in the United States, as it seeks to bring new therapies to market that can address unmet medical needs in the field of immunology.

Australia

Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.

KiRA Biotech

Company Details